PDCD1 and metastatic melanoma: The current study demonstrates that patients with metastatic melanoma and a SNP in PDCD1 (804C > T; rs2227981) have a significantly poorer OS after treatment with anti-PD-1 monotherapy, resulting in a 3-year survival rate of 51.8%, as compared to 71.0% for wild type patients.